Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies

Completed · Has a placebo group

Conditions studied: Symptomatic Vitreomacular Adhesion

In brief

The primary objective of this study is to assess visual function in up to 44 patients who have previously participated in either of the placebo controlled, ocriplasmin Phase III studies (TG-MV-006 or TG-MV-007).

Key facts

Study ID

NCT01287988

Run by

ThromboGenics

People needed

24

Starts

2011-05-01

Expected to finish

2011-10-01

Last updated by the study team

2017-01-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent obtained from the patient prior to inclusion in the follow-up study
• Previous participation in either of the placebo controlled, ocriplasmin Phase III studies (TG-MV-006 or TG-MV-007)

You may not qualify if…

• N/A

Where it is running

• Retinal Consultants of Houston — Houston, Texas, United States
• Universitaire Ziekenhuizen K.U. Leuven — Leuven, Belgium

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.